key: cord-0945011-jc5gg94c authors: Osipiuk, Jerzy; Azizi, Saara-Anne; Dvorkin, Steve; Endres, Michael; Jedrzejczak, Robert; Jones, Krysten A.; Kang, Soowon; Kathayat, Rahul S.; Kim, Youngchang; Lisnyak, Vladislav G.; Maki, Samantha L.; Nicolaescu, Vlad; Taylor, Cooper A.; Tesar, Christine; Zhang, Yu-An; Zhou, Zhiyao; Randall, Glenn; Michalska, Karolina; Snyder, Scott A.; Dickinson, Bryan C.; Joachimiak, Andrzej title: Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors date: 2020-08-07 journal: bioRxiv DOI: 10.1101/2020.08.06.240192 sha: 4422843690116b2bd5dc8404504d707b0fbbf8a6 doc_id: 945011 cord_uid: jc5gg94c The number of new cases world-wide for the COVID-19 disease is increasing dramatically, while efforts to contain Severe Acute Respiratory Syndrome Coronavirus 2 is producing varied results in different countries. There are three key SARS-CoV-2 enzymes potentially targetable with antivirals: papain-like protease (PLpro), main protease (Mpro), and RNA-dependent RNA polymerase. Of these, PLpro is an especially attractive target because it plays an essential role in several viral replication processes, including cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex (RTC), and disruption of host viral response machinery to facilitate viral proliferation and replication. Moreover, this enzyme is conserved across different coronaviruses and promising inhibitors have already been discovered for its SARS-CoV variant. Here we report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the enzyme from SARS-CoV-2 in both wild-type and mutant forms. These efforts include the first structures of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors, determined at 1.60–2.70 Angstroms. This collection of structures provides fundamental molecular and mechanistic insight to PLpro, and critically, illustrates details for inhibitors recognition and interactions. All presented compounds inhibit the peptidase activity of PLpro in vitro, and some molecules block SARS-CoV-2 replication in cell culture assays. These collated findings will accelerate further structure-based drug design efforts targeting PLpro, with the ultimate goal of identifying high-affinity inhibitors of clinical value for SARS-CoV-2. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is causing the COVID-19 pandemic. The virus belongs to the clade B of genus Betacoronavirus 1 and has large (+) sense ssRNA genome coding for 29 proteins. The 4 structural and 9-10 accessory proteins are translated from subgenomic RNAs produced from (-) sense ssRNA 2 . To reach the replication stage, the CoV-2 genomic (+) sense ssRNA is used as mRNA to ultimately produce 15 non-structural proteins (Nsps) from two large polyproteins, Pp1a (4,405 amino acids) and Pp1ab (7,096 amino acids) 3 . Pp1a is cleaved into the first 10 Nsps (Nsp11 is just a 7 residue peptide) and Pp1ab, which is made through a -1 ribosomal frame-shifting mechanism 4 . The resulting Pp1ab contains all 15 Nsps 5 . Therefore, proper polyprotein processing is essential for the release and maturation of the 15 Nsps and assembly into cytoplasmic, ER membrane-bound multicomponent replicase-transcriptase complex (RTC), which is responsible for directing the replication, transcription and maturation of the viral genome and subgenomic mRNAs 6, 7 . There are two distinctive cysteine proteases encoded by the CoV-2 genome that are essential to the virus proliferation cycle 6 PLpro is a domain of Nsp3 -a large multidomain protein that is an essential component of the RTC 7, 8 . The enzyme is located in Nsp3 between the SARS unique domain (SUD/HVR) and a nucleic acid-binding domain (NAB). It is highly conserved and found in all coronaviruses 8 , often in two copies, denoted as PL1pro and PL2pro 9, 10 . In CoV-2, Nsp3 contains 1,945 residues (~212 kDa) 3 . This cysteine protease cleaves peptide bonds between Nsp1 and Nsp2 (LNGG¯AYTR), Nsp2 and Nsp3 (LKGG¯APTK), and Nsp3 and Nsp4 (LKGG¯KIVN) liberating three proteins: Nsp1, Nsp2 and Nsp3 10 . The LXGG motif found in Pp1a/Pp1ab corresponds to the P4-P1 substrate positions of cysteine proteases and is essential for recognition and cleavage by PLpro 10, 11 PLpro exhibits multiple proteolytic and other functions 13 . In addition to processing Pp1a/Pp1ab, it was shown in SARS-and MERS-CoVs to have deubiquitinating activity, efficiently disassembling mono-, di-, and branched-polyubiquitin chains. It also has deISG15ylating (interferon-induced gene 15 ) activities. Both ubiquitin and ISG15 protein carry the PLpro recognition motif at their C-termini 14, 15 suggesting that removal of these modifications from host cells interferes with the host response to viral infection 10, [16] [17] [18] [19] . PLpro also inactivates TBK1, blocks NF-kappaB signaling, prevents translocation of IRF3 to the nucleus, inhibits the TLR7 signaling pathway, and induces Egr-1dependent up-regulation of TGF-β1 18,20 . Further illustrating the complex and diverse functions of the protein, in some reports, various PLpro roles are decoupled from its proteolytic activity 21,22 . Nevertheless, PLpro is a multifunctional protein having an essential role in processing of viral polyproteins, maturation, and assembly of the RTC, and it also may act on the host cell proteins by disrupting host viral response machinery to facilitate viral proliferation and replication. Due to the centrality of PLpro to viral replication, it is therefore an excellent candidate for therapeutic targeting. Ongoing efforts to identify antivirals for CoV-2 to date have focused mainly on three Nsp proteins identified as the key drug targets from previous SARS-and MERS-CoV studies: Nsp3 PLpro, Nsp5 Mpro, and Nsp12 RNA-dependent RNA polymerase. Here we discuss the case for targeting SARS- fortuitously, it has low sequence similarity to human enzymes. The sequence, structure, and functional conservation of PLpro suggests that therapeutics targeting SARS-CoV-2 PLpro may also be effective against related viruses with PLpro. In the past, this enzyme was structurally well characterized and currently there are over 40 structures of viral PLpro proteases in the Protein Data Bank 23 , mainly from SARS-CoV, that can aid structure-based drug discovery. In fact, the past 15 years of studies with PLpro have led to the identification of a number of inhibitors that were specific for SARS-CoV PLpro, but did not inhibit the MERS-CoV enzyme 7, 24, 25 . Unfortunately, these efforts have failed, thus far, to produce antivirals that can be useful for treatment of SARS-CoV-1 and -2 infections in humans. Here we report eight crystal structures, including the first structure of wild-type PLpro, the active site cysteine mutant, and their complexes with known and novel inhibitors of SARS-CoV-2 PLpro, determined at 1.60-2.70 Angstroms. These data reveal the structural basis of the enzyme with fine molecular details, and illustrate specific ligand recognition and interactions. The presented compounds inhibit PLpro peptidase activity in vitro, and most importantly, several of the novel inhibitors also block SARS-CoV-2 replication in cell culture. Collectively, these findings provide critical insights for further structure-based drug design efforts against PLpro to enable the design of even higher affinity inhibitors and, ultimately, human therapeutics. The CoV-2 PLpro sequence is 83% identical and 90% similar to SARS-CoV-1 and 31% identical and 49% similar to MERS-CoV and even more distant to SADS PLpro (Supplemental Fig. 1 ). Between SARS-and MERS-CoV many substitutions are quite conservative, but there are some that may have significant impact on protein stability, dynamics, ligand binding, and catalytic properties. Examples include Thr75 (Leu/Val), Pro129 (Ala/Ile), Tyr172 (His/Thr), Lys200 (Thr/Gln), Lys274 (Thr/Val) and Cys284 (Arg/Arg), with equivalent residues shown in parentheses for SARS/MERS PLpro, respectively. CoV-2 PLpro is a slightly basic, 315 residue protein with high content of cysteine residues (3.5%). Structures of Nsp3 PLpro were reported previously for SARS-, MERS-CoV, and other viruses 27 . The CoV-2 PLpro structure has "thumb-palm-fingers" architecture described before (Fig. 1) . This arrangement is similar to the ubiquitin specific proteases (USPs), one of the five distinct deubiquitinating enzyme (DUB) families, despite low sequence identities (~10%) 10, 27 . Briefly, the protein has two distinct domains: the small N-terminal ubiquitin-like (Ubl) domain and the "thumbpalm-fingers" catalytic domain (Fig. 1) . The Ubl domain consists of residues 1 to 60 with five bstrands, one a-helix, and one 3 10 -helix. In CoV-2 PLpro, chloride ion binds to a small loop formed by residues Thr9 -Ile14 at the interface with the catalytic domain. In different structures, Ub1 shows some conformational flexibility, though the specific function of this domain is not well understood. The larger catalytic domain is an extended right-hand scaffold with three characteristic subdomains. A thumb is comprised of six a-helices and a small b-hairpin. The fingers subdomain is the most complex; it is made of six b-strands and two a-helices and includes a zinc binding site. This structural zinc ion is coordinated by four cysteines located on two loops (Cys189, 192, 224, and 226) of two b-hairpins. Zinc binding is essential for structural integrity and protease activity 28 , but the conformation of this region varies most between different PLpro structures. The palm subdomain is comprised of six b-strands ( Fig. 1) with the catalytic residues Cys111, His272, and Asp286 located at the interface between the thumb and palm subdomains (Fig. 1 ). An important mobile β-turn/loop (Gly266 -Gly271) is adjacent to the active site that closes upon substrate and/or inhibitor binding. In the high resolution structure of PLpro C111S mutant, there is a phosphate ion bound to the active site at the N-terminus of helix a4 (contributing Cys111) that is coordinated by Trp106, Asn109, and His272. This site provides a good environment to stabilize C-terminal carboxylate group of the peptide cleavage product. In this structure, there is another phosphate ion bound to a thumb despite their structural differences, we found that all inhibit PLpro to varying degrees (IC 50 = 5.1-32.8 µM, Fig. 2 ). Given this suite of molecules that function as PLpro inhibitors in vitro, we next sought to test whether these molecules are also capable of inhibiting viral replication in live cells. We next performed CoV-2 virus replication assays using Vero E6 cells and measuring SARS CoV-2 replication. Surprisingly, not all compounds functioned in this assay, and their relative abilities to inhibit viral replication did not necessarily correlate directly with in vitro inhibition parameters toward PLpro. Compounds 1, 4, 5, 6, and 7 all proved capable of affecting the viability of cells and inhibiting virus replication. For compounds 1, 4, and 7 their EC50 values range from 1.5 to 8.0 µM ( Fig. 3A and 3B, and Supplemental Fig. 4 ). For example, PLpro inhibition by compound 1/GRL0617 is 14-times better than 4, but inhibition of virus replication is only two times higher. Moreover, compounds 2 and 3 are quite good inhibitors (IC50 values of 5.1 and 6.4 µM, respectively), but failed in the viral replication assay. Compound 5 was the weakest inhibitor in vitro (IC50 values of 32.8 µM), but was one of the best performers in the live viral replication assay (EC 50 2.5 µM). Differences in cell permeability and solubility could account for the disconnects between the in vitro biochemical assay data and viral replication data, but given the high degree of structural similarity between these molecules, these data indicate that further optimization is possible, especially in the case of compound 5, which is a relatively weak binder but solid inhibitor of the virus. More broadly, all of the compounds are promising and may need only small modification(s) in order to serve as preclinical lead compounds. To enable structure-based improvements of these molecules, we next aimed to get ligand-bound structures of as many of these lead compounds as possible. Based on these results, we believe it is critical to combine the in vitro biochemical assays to triage compounds with live viral replication assays. We were able to determine crystal structures of SARS-CoV-2 PLpro with non-covalent inhibitors 1, 2, and 3 (Supplemental Table 1 ) three using C111S mutant and one wild-type enzyme (PDB ids: 7JIR, 7JIT, 7JIV, 7JIW). The structure with compound 3 was solved in both wild-type and mutant forms. The electron density for the ligand, protein, solvent, and bound acetate ion is excellent (Fig. 4 ). All three compounds bind to the same site as observed previously for GRL0617 in complex with SARS-CoV PLpro (PDB id: 3E9S) 29 and now determined for 1 in complex with SARS-CoV-2 PLpro (Fig. 4A ). The structure of 2 bound to the PLpro C111S mutant was determined at 1.95 Å (PDB id: 7JIT), the highest resolution for all complexes to date, and this structure will be used here as a reference ( Fig. 4B and Supplemental Fig. 5A ). Compound 2 binds to the groove on the surface of PLpro near the active site, ~8 Å apart from Cys/Ser111, overlapping with S4/S3 protein subsites (corresponding the substrate positions P4/P3), that are critical for recognition of the leucine residue in the LXGG motif (Fig. 4E ). The ubiquitin peptide-binding site is a solvent-exposed groove: wide at S4 site, solvent exposed at P3 site, and very narrow at P2 and P1 sites (Fig. 4E) . Because of the high resolution achieved, we observe extensive interactions between compound 2 and the protein involving direct as well as water-mediated hydrogen bonds and van der Waals contacts, noting some additional interactions provided by the carbamylurea moiety in 2. As compared with unliganded protein, the main chain and side chains of several residues significantly adjust to accommodate the ligand (Arg166, Glu167, Tyr268, Gln269, Fig. 4B and Supplemental Fig. 5A ). Direct hydrogen bonds are found between Glu167 and Tyr268 and two nitrogen and oxygen atoms of the carbamylurea moiety, respectively (Fig. 4B ). As compared with 1/GRL0617 compound 2 makes all the same interactions and provides additional four hydrogen bonds. Intriguingly, however, the IC 50 value for 1 is ~2 times lower than for 2, despite 2 making more interactions with the protein. Asp164 hydrogen bonds with another amino group in the linker between two aromatic rings and main-chain amino group of Gln269 hydrogen bonds to oxygen atom of that linker. Lys157 makes water-mediated hydrogen bond to the carbamylurea moiety. This water molecule also coordinates Glu167. Interestingly, this residue (equivalent of Glu168 in SARS PLpro) seems to play an important role in Ub1 core recognition, and mutations can cause a significant loss of DUB activity. The aromatic rings of 2 make several hydrophobic interactions, specifically with Pro248, Tyr268, aliphatic regions of the side chain of Gln269, and Asp164. Curiously, there is also an acetate ion packing in between 2 and protein residues. This ion is coordinated by Arg166 and Glu167. The ligand binding site offers a number of opportunities to improve ligand affinity (water and acetate binding site) and potential linking to the active site for covalent attachment, many of which were not explicitly indicated by previous work with SARS. Fig. 1 ). Therefore, ligands that bind to hydrophobic S4 site and make hydrophilic interactions with PLpro surface residues may be good candidates for inhibitors of the PLpro enzyme. The S3 site can accept any residue because it is solvent exposed, but would prefer hydrophilic side chain (Arg, Lys, Asn). The peptide then follows the path to the active site that becomes narrower and can accept only two glycine residues in P1 and P2. The P1' again is on the protein surface and can accept any residue. The interesting requirement is that the peptide binding to S1 -S4 sites must be in extended/linear conformation, placing noteworthy constrains on designing inhibitors targeting the active site. In summary in this report we have presented a substantial high resolution structural, biochemical, and virus replication studies of PLpro cysteine protease from SARS-CoV-2 and describe seven compounds that inhibit enzyme in in vitro biochemical assay based on the cleavage of the LXGG recognition peptide, a subset of these inhibit virus replication. We have determined apo-structures of wild-type enzyme and inactive mutant in which single sulfur atom was replaced by oxygen (C111S). The gene cloning, protein expression and purification were performed as reported previously The ethylene glycol (protein-inhibitor crystals) and flash-cooled in liquid nitrogen. Single-wavelength x-ray diffraction data were collected at 100 K temperature at the 19-ID beamline of the Structural Biology Center at the Advanced Photon Source at Argonne National Laboratory using the program SBCcollect. The diffraction images were recorded from all crystal forms on the PILATUS3 X 6M detector using 0.3° rotation and 0.3 sec exposure (with the exception of the first WT PLpro crystal where data were collected using 0.5° rotation and 0.5 sec exposure). The intensities were integrated and scaled with the HKL3000 suite 2 . Intensities were converted to structure factor amplitudes in the truncate program 3,4 from the CCP4 package 5 . The structures were determined by molecular replacement using HKL3000 suite incorporating the following programs: MOLREP 6 , SOLVE/RESOLVE 7 and ARP/wARP 8 . The initial solutions were refined, both rigid-body refinement and regular restrained refinement by REFMAC program 9 as a part of HKL3000. The coordinates of SARS coronavirus PLpro (PDB id: 5Y3Q) were used as the starting model for the first wild-type protein structure solution. Several rounds of manual adjustments of structure models using COOT 10 and refinements with REFMAC program 9 from CCP4 suite 5 were done. The models including the ligands were manually adjusted using COOT and then iteratively refined using COOT and REFMAC. The stereochemistry of the structure was validated with PHENIX suite 11 incorporating MOLPROBITY 12 tools. Throughout the refinement, the same 5% of reflections were kept out from the refinement. The stereochemistry of the structure was checked with PROCHECK 13 and the Ramachandran plot and validated with the PDB validation server. A summary of data collection and refinement statistics is given in Supplemental Table 1 . To a solution of K2CO3 (18.2 mg, 0.132 mmol, 2.0 equiv) in H2O (0.12 mL) and acetone (0.48 mL) at 0 °C was added acryloyl chloride (0.011 mL, 0.132 mmol, 2.0 equiv). Amine 1 (20.0 mg, 0.066 mmol, 1.0 equiv) was then added dropwise at 0 °C as a solution in acetone (0.2 mL) and the reaction mixture was allowed to stir at 0 °C for 10 min. Upon completion, the reaction contents were quenched by the addition of saturated aqueous NH4Cl (10 mL), diluted with CH2Cl2 (10 mL), and poured into a separatory funnel. The two phases were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined organic extracts were then dried (Na2SO4), 3-nitro-5-(trifluoromethyl)benzoic acid (0.752 g, 3.20 mmol, 1.0 equiv) was suspended in CH2Cl2 (14 mL) under an argon atmosphere at 23 °C. Then, DMF (2 drops) was added, followed by slow addition of oxalyl chloride (0.300 mL, 0.444 g, 3.50 mmol, 1.1 equiv). The resulting solution was stirred at 23 °C for 1 h before complete dissolution of the starting material was observed. The mixture was then concentrated to dryness, back-filled with argon, redissolved in CH2Cl2 (10 mL) and cooled to 0 °C. Then, naphthylamine (0.500 g, 3.49 mmol, 1.1 equiv) was added in a single portion and the solution was warmed to 23 °C and stirred vigorously at this temperature for 2 h. The resulting precipitate was filtered and washed with cold CH2Cl2 (2 ´ 10 mL). The CH2Cl2-containing filtrate was discarded, and the filter cake was then thoroughly washed with warm (50 °C) EtOAc (4 ´ 20 mL). The filtrate was concentrated to afford the desired amide To a solution of 6 (8.5 mg, 0.018 mmol, 1.0 equiv) in THF (0.20 mL) at 23 °C was added nbutylamine (0.01 mL, 0.036 mmol, 2.0 equiv) and the reaction mixture was allowed to stir for 5 min. Upon completion, the reaction contents were quenched by the addition of H2O (5 mL), diluted with CH2Cl2 (5 mL), and poured into a separatory funnel. The two phases were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 30 mL A solution of Boc glycine (507.8 mg, 2.89 mmol, 1.0 equiv), oxyma and purification by column chromatography (silica gel, 2-10% MeOH:CH 2 Cl 2 ) yielded S1 in 78% purity as analyzed by LCMS. For further purification, the impure mixture was dissolved in minimal CH 2 Cl 2 , washed with water and brine. The organic layer was cooled to 0 °C and the white precipitate was filtered to yield pure S1 (0.562 g, 76% yield). S1: 1 A solution of S1 (47.8 mg, 0.143 mmol) in 20% TFA:CH 2 Cl 2 (2 mL) was stirred at 23 °C for 30 min, followed by dilution with CH 2 Cl 2 (10 mL) and solvent removal by rotary evaporation. Dilution with CH 2 Cl 2 (15 mL) and solvent removal by rotary evaporation was repeated two more times to remove residual TFA. The resultant crude was resuspended in DMF (5 mL A solution of S5 (22.7 mg, 26.6 µmol, 1.0 equiv) in 10% Piperidine:CH 2 Cl 2 (2 mL) was stirred for 15 min at 23 °C and followed with solvent removal by rotary evaporation. Dilution with DMF (5 mL) and solvent removal by rotary evaporation was repeated two more times to remove residual piperidine. The resultant crude was resuspended in DMF (2 mL), and i-Pr 2 NEt (18.5 µL, 0.11 mmol, 4 equiv) and acetic anhydride (10.0 µL, 0.11 mmol, 4 equiv) were added at 23 °C. The reaction mixture was stirred for 1 h at 23 °C, diluted by EtOAc (20 mL), and then washed by aqueous HCl (pH ~2-3). The aqueous layer was further extracted by EtOAc (2 ´ 20 mL), the combined organic layers were dried over Na 2 SO 4 , and then evaporated to give a crude product. Purification by column chromatography (silica gel, 2-15% MeOH in 1:1 EtOAc:CH 2 Cl 2 ) yielded S6 (9.7 mg, 56% yield). S6: 1 A solution of S6 (11.2 mg, 16.6 µmol, 1.0 equiv) in 20% TFA:CH 2 Cl 2 (2 mL) was stirred at 23 °C for 30 min, followed by dilution with CH 2 Cl 2 (5 mL) and solvent removal by rotary Vero E6 cells (ATCC) were infected under biosafety level 3 conditions with SARS-CoV-2 (nCoV/Washington/1/2020, kindly provided by the National Biocontainment Laboratory, Galveston, TX). Immunostaining was performed on 10% NBF fixed SARS-CoV-2 infected cells in 96-well plate. After fixation, 10% NBF was removed, and cells were washed with PBS, followed by Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group The Architecture of SARS-CoV-2 Transcriptome Understanding COVID-19 via comparative analysis of dark proteomes of SARS-CoV-2, human SARS and bat SARS-like coronaviruses The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism Structural and functional conservation of the programmed -1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2) The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. bioRxiv Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein Coronavirus genomics and bioinformatics analysis. Viruses Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity Snapshot of the evolution and mutation patterns of SARS-CoV-2. bioRxiv Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6 Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating activity of SARS-CoV papain-like protease H NMR (400 MHz, DMSO-d6) δ 10.47 (s, 1 H), 8.03-7.92 (m, 2 H), 7.91-7.84 (m, 1 H), 7.61-7.45 (m, 6 H) mL) at 23 °C was added 4-nitrophenyl chloroformate (21.8 mg, 0.108 mmol, 1.5 equiv) and the reaction mixture was allowed to stir at 23 °C for 1 h. Upon completion, the solution was concentrated directly. Purification of the resultant residue by flash column chromatography (silica gel, hexanes:EtOAc, 2:1) afforded compound 6 (32.4 mg, 97% yield) as a white solid 778 cm -1 ; 1 H NMR (500 MHz, CDCl3) δ 8.19-8.16 (m, 1 H), 8.15-8.12 (m, 2 H 35 (s, 3 H), 1.74 (d, J = 6.8 Hz, 3 H). 13 C NMR (126 MHz, CDCl3) Protein production for structural genomics using E. coli expression HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes Treatment of Negative Intensity Observations A statistic for local intensity differences: robustness to anisotropy and pseudo-centering and utility for detecting twinning Overview of the CCP4 suite and current developments Molecular replacement with MOLREP SOLVE and RESOLVE: automated structure solution, density modification and model building ARP/wARP and automatic interpretation of protein electron density maps The PDB_REDO server for macromolecular structure model optimization Coot: model-building tools for molecular graphics PHENIX: a comprehensive Python-based system for macromolecular structure solution MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes PROCHECK: a program to check the stereochemical quality of protein structures Comparative genomics of the lactic acid bacteria Unexpected Reactivity of N-Acyl-Benzotriazoles with Aromatic Amines in Acidic Medium (ABAA Reaction) A dithienylethene-based rewritable hydrogelator We thank the members of the SBC at Argonne National Laboratory, especially Darren Sherrell and Alex Lavens for their help with setting beamline and data collection at beamline 19-ID.